Tyrosine Kinases as Druggable Targets in Cancer / / edited by Huan Ren.
Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | London, United Kingdom : : IntechOpen,, 2019. |
| Year of Publication: | 2019 |
| Language: | English |
| Physical Description: | 1 online resource (134 pages) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 00911nam a2200289 i 4500 | ||
|---|---|---|---|
| 001 | 993548223904498 | ||
| 005 | 20221006103648.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 221006s2019 enk o 000 0 eng d | ||
| 020 | |a 1-83962-219-9 | ||
| 020 | |a 1-78984-809-1 | ||
| 035 | |a (CKB)4100000009913396 | ||
| 035 | |a (NjHacI)994100000009913396 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/67013 | ||
| 035 | |a (EXLCZ)994100000009913396 | ||
| 040 | |a NjHacI |b eng |e rda |c NjHacl | ||
| 041 | 0 | |a eng | |
| 050 | 4 | |a RC261 |b .T976 2019 | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 100 | 1 | |a Ren, Huan |4 edt | |
| 245 | 0 | 0 | |a Tyrosine Kinases as Druggable Targets in Cancer / |c edited by Huan Ren. |
| 260 | |b IntechOpen |c 2019 | ||
| 264 | 1 | |a London, United Kingdom : |b IntechOpen, |c 2019. | |
| 300 | |a 1 online resource (134 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | |a Description based on publisher supplied metadata and other sources. | ||
| 520 | |a Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment. | ||
| 546 | |a English | ||
| 650 | 0 | |a Oncology. | |
| 653 | |a Oncology | ||
| 776 | |z 1-78984-808-3 | ||
| 700 | 1 | |a Ren, Huan, |e editor. | |
| 906 | |a BOOK | ||
| ADM | |b 2023-02-22 20:33:32 Europe/Vienna |f system |c marc21 |a 2019-12-08 04:53:41 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338819690004498&Force_direct=true |Z 5338819690004498 |b Available |8 5338819690004498 | ||